Tags

Type your tag names separated by a space and hit enter

[Depression and Parkinson's disease: neurobiologic foundations and therapeutic management].
Neurologia. 1996 Nov; 11(9):332-40.N

Abstract

The prevalence of depression in Parkinson's disease (PD) is estimated to be around 40% and generally takes the form of dysthymia. Although psychological factors probably contribute to depression, data point to a relation to structural and biochemical changes linked to PD. Thus, the onset of motor impairment is often preceded by a depressive episode, although there is no consistency between the seriousness of motor disability and depression. Furthermore, depression aggravates the memory and language impairments of PD and is thought to be a risk factor for developing dementia. Regional cerebral blood flow abnormalities in the medial frontal and cingulate cortices and low 5-HIIA concentrations in cerebro-spinal fluid suggest that degeneration of the mesocorticolimbic dopaminergic system as well as dorsal raphe changes may be implicated. Assessment of depression in PD is difficult, as none of the currently available scales were specifically designed for patients with this disease Furthermore, there is a lack of well-controlled studies showing that current antidepressants are effective in PD patients or are safe for use when the motor, cognitive and autonomic impairments of PD are present.

Authors+Show Affiliations

Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

spa

PubMed ID

9004744

Citation

Giménez-Roldán, S, et al. "[Depression and Parkinson's Disease: Neurobiologic Foundations and Therapeutic Management]." Neurologia (Barcelona, Spain), vol. 11, no. 9, 1996, pp. 332-40.
Giménez-Roldán S, Dobato JL, Mateo D, et al. [Depression and Parkinson's disease: neurobiologic foundations and therapeutic management]. Neurologia. 1996;11(9):332-40.
Giménez-Roldán, S., Dobato, J. L., Mateo, D., González Alvarez, M., Novillo Infantes, M. J., & Giménez-Zuccarelli, M. (1996). [Depression and Parkinson's disease: neurobiologic foundations and therapeutic management]. Neurologia (Barcelona, Spain), 11(9), 332-40.
Giménez-Roldán S, et al. [Depression and Parkinson's Disease: Neurobiologic Foundations and Therapeutic Management]. Neurologia. 1996;11(9):332-40. PubMed PMID: 9004744.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Depression and Parkinson's disease: neurobiologic foundations and therapeutic management]. AU - Giménez-Roldán,S, AU - Dobato,J L, AU - Mateo,D, AU - González Alvarez,M, AU - Novillo Infantes,M J, AU - Giménez-Zuccarelli,M, PY - 1996/11/1/pubmed PY - 1996/11/1/medline PY - 1996/11/1/entrez SP - 332 EP - 40 JF - Neurologia (Barcelona, Spain) JO - Neurologia VL - 11 IS - 9 N2 - The prevalence of depression in Parkinson's disease (PD) is estimated to be around 40% and generally takes the form of dysthymia. Although psychological factors probably contribute to depression, data point to a relation to structural and biochemical changes linked to PD. Thus, the onset of motor impairment is often preceded by a depressive episode, although there is no consistency between the seriousness of motor disability and depression. Furthermore, depression aggravates the memory and language impairments of PD and is thought to be a risk factor for developing dementia. Regional cerebral blood flow abnormalities in the medial frontal and cingulate cortices and low 5-HIIA concentrations in cerebro-spinal fluid suggest that degeneration of the mesocorticolimbic dopaminergic system as well as dorsal raphe changes may be implicated. Assessment of depression in PD is difficult, as none of the currently available scales were specifically designed for patients with this disease Furthermore, there is a lack of well-controlled studies showing that current antidepressants are effective in PD patients or are safe for use when the motor, cognitive and autonomic impairments of PD are present. SN - 0213-4853 UR - https://www.unboundmedicine.com/medline/citation/9004744/[Depression_and_Parkinson's_disease:_neurobiologic_foundations_and_therapeutic_management]_ L2 - http://www.diseaseinfosearch.org/result/2199 DB - PRIME DP - Unbound Medicine ER -